Mycophenolate Mofetil Monotherapy in Membranous Nephropathy: A 1-Year Randomized Controlled Trial

American Journal of Kidney Diseases

Volumn 52, Issue 4, 2008, Pages 699-705

  Dussol, Bertrand ^a   Morange, Sophie ^b   Burtey, Stéphane ^a   Indreies, Monica ^a   Cassuto, Elisabeth ^c   Mourad, Georges ^d   Villar, Emmanuel ^e   Pouteil Noble, Claire ^e   Karaaslan, Huseyin ^f   Sichez, Hélène ^a   Lasseur, Catherine ^g   Delmas, Yashou ^g   Nogier, Marie Béatrice ^h   Fathallah, Mohamed ^b   Loundou, Anderson ⁱ   Mayor, Valérie ^j   Berland, Yvon ^a  

^a HÔPITAL DE LA CONCEPTION   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^c PASTEUR HOSPITAL   (France)

^d LAPEYRONIE HOSPITAL   (France)

^e HOSPICES CIVILS DE LYON   (France)

^f EDOUARD HERRIOT HOSPITAL   (France)

^g HÔPITAL PELLEGRIN   (France)

^h CHU RANGUEIL   (France)

ⁱ AIX MARSEILLE UNIVERSITY   (France)

^j Roche   (France)

more..

Author keywords

Membranous nephropathy; mycophenolate mofetil; nephrotic syndrome; randomized trial

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; ENALAPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LOOP DIURETIC AGENT; LOSARTAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICARDIPINE; PERINDOPRIL; PRAVASTATIN; RAMIPRIL;

ADULT; AGED; ANEMIA; ARTICLE; BRONCHITIS; BULLOUS SKIN DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; CYTOLYSIS; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; EDEMA; EVALUATION; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HERPES ZOSTER; HUMAN; HYPERTENSION; HYPOTENSION; KIDNEY BIOPSY; LUNG SMALL CELL CANCER; MALE; MEMBRANOUS GLOMERULONEPHRITIS; MYALGIA; NAUSEA; PROBABILITY; PROSPECTIVE STUDY; PROTEIN RESTRICTION; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; REMISSION; SIDE EFFECT; SODIUM RESTRICTION; VOMITING;

EID: 52049085769     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2008.04.013     Document Type: Article

References (27)

1. Haas M., Meehan S.M., Karrison T.G., and Spargo B.H. Changing etiologies of unexplained adult nephrotic syndrome: A comparison of renal biopsy findings from 1976-1979 and 1995-1997. Am J Kidney Dis 30 (1997) 621-631
2. Kincaid-Smith P. Pharmacological management of membranous nephropathy. Curr Opin Nephrol Hypertens 11 (2002) 149-154
3. Muirhead N. Management of idiopathic membranous nephropathy: Evidence-based recommendations. Kidney Int Suppl 70 (1999) S47-S55
4. Glassock R.J. The treatment of idiopathic membranous nephropathy: A dilemma or a conundrum. Am J Kidney Dis 44 (2004) 562-566
5. Cattran D.C. Idiopathic membranous nephropathy. Kidney Int 59 (2001) 1983-1994
6. Shiiki H., Saito T., Nishitani Y., et al. Prognosis and risk factors for idiopathic membranous nephropathy with nephrotic syndrome in Japan. Kidney Int 65 (2004) 1400-1407
7. Cattran D.C., Pei Y., Greenwood C.M., et al. Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis. Kidney Int 42 (1992) 960-966
8. Torres A., Dominguez-Gil B., Carreno A., et al. Conservative versus immunosuppressive treatment of patients with idiopathic membranous nephropathy. Kidney Int 61 (2002) 219-227
9. Ahuja M., Goumenos D., Shortland J.R., Gerakis A., and Brown C.B. Does immunosuppression with prednisolone and azathioprine alter the progression of idiopathic membranous nephropathy?. Am J Kidney Dis 34 (1999) 521-529
10. Perna A., Schieppati A., Zamora J., Giuliano G., Braun N., and Remuzzi G. Immunosuppressive treatment for idiopathic membranous nephropathy: A systematic review. Am J Kidney Dis 44 (2004) 385-401
11. Praga A., Barrio V., Fernandez Juarez G., Luno J., and Grupo Espanol de Estudio de le Nephropatia membranosa. Tacrolimus monotherapy in membranous nephropathy: A randomized controlled trial. Kidney Int 71 (2007) 924-930
12. Jha V., Ganguli A., Saha T., et al. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol 18 (2007) 1899-1904
13. Penny M.J., Boyd R.A., and Hall B.M. Mycophenolate mofetil prevents the induction of active Heymann nephritis: Association with Th2 cytokine inhibition. J Am Soc Nephrol 9 (1998) 2272-2282
14. Ziswiler R., Steinmann-Niggli K., Kappeler A., et al. Mycophenolic acid: A new approach to the therapy of experimental mesangial proliferative glomerulonephritis. J Am Soc Nephrol 9 (1998) 2055-2066
15. Miller G., Zimmermann R., Radhakrishnan, and Appel G. Use of mycophenolate mofetil in resistant membranous nephropathy. Am J Kidney Dis 36 (2000) 250-256
16. Choi M.J., Eustace J.A., Gimenez L.F., et al. Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int 61 (2002) 1098-1114
17. Polenakovic M., Grcevska L., and Dzikova S. Mycophenolate mofetil in treatment of idiopathic stages III-IV membranous nephropathy. Nephrol Dial Transplant 18 (2003) 1234-1235
18. Segarra A., Amoedo M.L., Martinez Garcia J.M., et al. Efficacy and safety of 'rescue therapy' with mycophenolate mofetil in resistant primary glomerulonephritis-A multicenter study. Nephrol Dial Transplant 22 (2007) 1351-1360
19. Sahin G.M., Sahin S., Kantarci G., and Ergin H. Mycophenolate mofetil treatment of therapy-resistant glomerulopathies. Nephrology (Carlton) 12 (2007) 285-288
20. Cattran D. Management of membranous nephropathy: When and what for treatment?. J Am Soc Nephrol 16 (2005) 1188-1194
21. Cattran D.L., Appel G.B., Hebert L.A., et al. Cyclosporine in patients with steroid-resistant membranous nephropathy: A randomized trial. Kidney Int 59 (2001) 1484-1490
22. Ponticelli C., Zucchelli P., Imbasciati E., et al. Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med 310 (1984) 946-950
23. Ponticelli C., Passerini P., Salvadori M., et al. A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy. Am J Kidney Dis 47 (2006) 233-240
24. Schieppati A., Mosconi L., Perna A., et al. Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med 329 (1993) 85-89
25. Granger D.K., ERL B 301 Renal Transplant Study Group, and ERL B 302 Renal Transplant Study Group. Enteric-coated mycophenolate sodium: Results of two pivotal global multicenter trials. Transplant Proc 33 (2001) 3241-3244
26. Branten A.J., du Buf-Vereijken P.W., Vervloet M., and Wetzels J.F. Mycophenolate mofetil in idiopathic membranous nephropathy: A clinical trial with comparison to a historic control group treated with cyclophosphamide. Am J Kidney Dis 50 (2007) 248-256
27. Chan T.M., Lin A.W., Tang S.C.W., et al. Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndrome. Nephrology (Carlton) 12 (2007) 576-581